StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Viread (tenofovir disoproxil fumarate by Quarter

Viread (tenofovir disoproxil fumarate — legacy breakout) — Europe sales ($M) ($M)

QuarterlyAnnual

Gilead Sciences Viread (tenofovir disoproxil fumarate: $5M in Q4 2023, down 16.7% from a year earlier. That is the lowest of the 29 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2023
5
Period ended Dec 31, 2023
Change on a year earlier
-16.7%
6 in Q4 2022
History
29 quarters
Since Q4 2016
Sources
21
Documents cited below

Where the Q4 2023 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2024-02-23) ↗

Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedViread (tenofovir disoproxil fumarate — legacy breakout) — Europe sales ($M) ($M)Year on yearSource
Q4 2023Dec 31, 20235-16.7%Form 10-K (filed 2024-02-23) ↗
Q3 2023Sep 30, 202350.0%Form 10-Q (filed 2023-11-07) ↗
Q2 2023Jun 30, 202360.0%Form 10-Q (filed 2023-08-04) ↗
Q1 2023Mar 31, 202360.0%Form 10-Q (filed 2023-05-03) ↗
Q4 2022Dec 31, 202260.0%Form 10-K (filed 2024-02-23) ↗
Q3 2022Sep 30, 20225-28.6%Form 10-Q (filed 2023-11-07) ↗
Q2 2022Jun 30, 20226-25.0%Form 10-Q (filed 2023-08-04) ↗
Q1 2022Mar 31, 20226-14.3%Form 10-Q (filed 2023-05-03) ↗
Q4 2021Dec 31, 20216-14.3%Form 10-K (filed 2024-02-23) ↗
Q3 2021Sep 30, 20217-12.5%Form 10-Q (filed 2022-11-02) ↗
Q2 2021Jun 30, 202180.0%Form 10-Q (filed 2022-08-08) ↗
Q1 2021Mar 31, 20217-36.4%Form 10-Q (filed 2022-05-04) ↗
Q4 2020Dec 31, 20207-41.7%Form 10-K (filed 2023-02-22) ↗
Q3 2020Sep 30, 20208-46.7%Form 10-Q (filed 2021-11-03) ↗
Q2 2020Jun 30, 20208-71.4%Form 10-Q (filed 2021-08-05) ↗
Q1 2020Mar 31, 202011-21.4%Form 10-Q (filed 2020-05-06) ↗

Cite this data

StockData. (2026). Gilead Sciences Viread (tenofovir disoproxil fumarate ($M), quarterly Q4 2016–Q4 2023 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-viread-eu

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.